Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation: a French Multicentric Prospective Observational Study
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms SPECTRA
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 24 Jun 2024 Status changed from not yet recruiting to recruiting.
- 11 Jun 2024 New trial record